Website is intended for physicians



Aim: was to determine the influence of blood plasma fibrinogen level on results of the left main coronary artery stenting.

Material and methods: clinical, laboratory and angiographic parameters of 819 patients after elective stenting of the unprotected left main coronary artery were used. The end-point was target lesion failure (TLF), including adverse events as repeated revascularization of the target lesion (TLR), myocardial infarction (MI) and death from cardiac causes.

Results: in 5 years follow-up period, end-point was achieved in 158 cases (19,3%). Independent predictors of TLF were: SyntaxScore > 32 (HR 1,089 95% CI 1,029-1,153, p = 0,003), creatinine level (HR 1,009 95% CI 1,004-1,013, p=0,001) and fibrinogen level (HR 1,4 95% CI 1,169-1698, p=0001). According to results of the Kaplan-Meier analysis, the cumulative probability of the TLF was higher in patients with fibrinogen values greater than 3,48 g/L (log-rank 0,001).

Conclusion: blood plasma fibrinogen level was an independent predictor of the TLF after left main coronary artery stenting. Increase in the level of blood fibrinogen for each 1 g/L led to an increase in the risk of TLF by 1,4 times per month.



1.     Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63: 619.

2.     Kurtul A, Yarlioglues M, Murat SN, et al.The associationof plasmafibrinogen with the extent andcomplexity of coronary lesions in patients with acute coronary syndrome. Kardiol Pol. 2016; 74: 338-345.

3.     Jiang P, Gao Z, Zhao W, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chinese Medical Journal. 2019; 132(8).

4.     Ang L, Behnamfar O, Palakodeti S, et al. Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. JAHA. 2017; 117.

5.     Gershlick A, Kandzar D, Banning A, et al. Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site. Results From the EXCEL Trial. JACC. 2018; 11(13).

6.     Castell JV, Gomez-Lechon MJ, David M, et al. Acutephase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990; 12: 1179-1186.

7.     Rahel BM, Visseren FLJ, Suttorp M, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003; 60: 136-140.

8.     Ou Baiqing, Yang Yulian, Chen Zhimin, et al. The Effect of Lumbrokinase on the Fibrinogen Increase Following Percutaneous Coronary Intervention. Chinese Journal of new Drugs. 2004; 13(12): 1158-60.

9.     Shi Y, Wu Y, Bian C, et al. Predictive value of plasma fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010; 37: 178-183.

10.   Corrado E, Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg. 2005; 105: 567-579.

11.   Ehtisham M, Mattheus R, Enright K, et al. Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding Following Percutaneous Coronary Intervention. The American Journal of Cardiology. 2016; 117(10): 1575-1581.

12.   Otsuka M, Hayashi Y, Ueda H, et al. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis. 2002; 164: 371-378.

13.   Kavitha S, Sridhar M, Satheesh S. Periprocedural plasma fibrinogen levels and coronary stent outcome. Indian heart journal. 2015; 67: 440-443. (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы